BRD4 Inhibitor Inhibits Colorectal Cancer Growth and Metastasis by Hu, Yuan et al.
Int. J. Mol. Sci. 2015, 16, 1928-1948; doi:10.3390/ijms16011928 
 
International Journal of 




BRD4 Inhibitor Inhibits Colorectal Cancer Growth  
and Metastasis 
Yuan Hu 1,2,†, Jieqiong Zhou 1,†, Fei Ye 2, Huabao Xiong 3, Liang Peng 3, Zihan Zheng 4,  
Feihong Xu 3, Miao Cui 2, Chengguo Wei 5, Xinying Wang 1, Zhongqiu Wang 1, Hongfa Zhu 2, 
Peng Lee 6, Mingming Zhou 7, Bo Jiang 1,* and David Y. Zhang 2,* 
1 Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, 
Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Road, Guangzhou 510515, 
China; E-Mails: drhuyuan@gmail.com (Y.H.); zhoujieqiong2008@sina.com (J.Z.); 
sunwingwxy@163.com (X.W.); wangzq815@gmail.com (Z.W.) 
2 Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; 
E-Mails: fei.ye@mssm.edu (F.Y.); miao.cui@mssm.edu (M.C.); hongfa.zhu@mountsinai.org (H.Z.) 
3 Department of Medicine, Immunology Institute, Icahn School of Medicine at Mount Sinai,  
New York, NY 10029, USA; E-Mails: huabao.xiong@mssm.edu (H.X.);  
liang.peng@mssm.edu (L.P.); feihong.xu@mssm.edu (F.X.) 
4 College of Arts and Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, 
USA; E-Mail: zihanz@live.unc.edu 
5 Departments of Medicine Bioinformatics Core, Icahn School of Medicine at Mount Sinai,  
New York, NY 10029, USA; E-Mail: chengguo.wei@mssm.edu 
6 Departments of Pathology, Urology, NYU Cancer Institute, New York Harbor Healthcare System, 
New York University, School of Medicine, New York, NY 10010, USA;  
E-Mail: Peng.Lee@nyumc.org 
7 Department of Structural and Chemical Biology, Icahn School of Medicine at Mount Sinai,  
New York, NY 10029, USA; E-Mail: ming-ming.zhou@mssm.edu 
† These authors contributed equally to this work. 
* Authors to whom correspondence should be addressed;  
E-Mails: drjiang@163.com (B.J.); david.zhang@mssm.edu (D.Z.);  
Tel.: +1-212-659-8137 (D.Z.). 
Academic Editor: Jack Schalken 
OPEN ACCESS
Int. J. Mol. Sci. 2015, 16 1929 
 
 
Received: 6 November 2014 / Accepted: 8 January 2015 / Published: 16 January 2015 
 
Abstract: Post-translational modifications have been identified to be of great importance 
in cancers and lysine acetylation, which can attract the multifunctional transcription factor 
BRD4, has been identified as a potential therapeutic target. In this paper, we identify that 
BRD4 has an important role in colorectal cancer; and that its inhibition substantially wipes 
out tumor cells. Treatment with inhibitor MS417 potently affects cancer cells, although 
such effects were not always outright necrosis or apoptosis. We report that BRD4 
inhibition also limits distal metastasis by regulating several key proteins in the progression 
of epithelial-to-mesenchymal transition (EMT). This effect of BRD4 inhibitor is 
demonstrated via liver metastasis in animal model as well as migration and invasion 
experiments in vitro. Together, our results demonstrate a new application of BRD4 
inhibitor that may be of clinical use by virtue of its ability to limit metastasis while also 
being tumorcidal. 




Colorectal cancer (CRC) is the third most prevalent form of cancer globally and accounts for 
approximately 8% of all estimated new cases of cancer in 2014 [1]. Currently, CRC is commonly 
treated using combinations of surgery, chemotherapy and radiotherapy. However, chemotherapy drugs, 
such as fluorouracil (5-FU) and irinotecan (commonly used as part of the FOLFIRI regimen), have 
negative effects on healthy tissue at the doses required for successful tumor elimination and may also 
be promoting pathways that lead to tumor resistance, through the activation of pro-inflammatory and 
anti-apoptotic factors [2–4]. Surgical interventions may not be able to clear out all cancerous tissue, 
and the mortality rate of CRC, especially in cases with distant metastases, still remains high [1].  
As a result, it is clear that novel therapies for treating CRC that target the tumor cells in different ways 
are urgently needed. 
Epigenetic modifications, such as DNA methylation and posttranslational histone modifications, 
have been shown to affect almost every component of gene regulation. Histone (de)acetylation, which 
functions importantly in chromatin remodeling and gene activation [5], is best characterized in CRC [6].  
In 1999, bromodomains (BRDs), a group of protein modules which contain ~110 amino acids were 
reported as the first protein modules to recognize acetylated lysine in histone through the unusual  
left-handed four-helix bundle structure [7,8]. To date, a total of 61 BRDs have been clustered into 
eight human BRD families based on structure and sequence similarity [9]. The bromodomain and extra 
terminal (BET) family including BRD2, BRD3, BRD4 and BRDT is one of them and features  
a distinctive domain architecture of two tandem amino-terminal bromodomains that exhibit high levels 
of sequence conservation [10]. BRD2 and BRD4 have been reported to be involved in cell cycle 
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progression, given the evidence that binding of BRD2 and BRD4 to acetylated chromatin persists even 
during mitosis when chromatin is highly condensed and transcription is interrupted [11,12]. BRD2  
is underexpressed in some subtypes of human lymphoma [12]. Recently, BRD4 has been demonstrated 
to play a key role in the pathogenesis of several different types of cancers and is considered to be  
a compelling therapeutic target [10]. BRD4 has been identified functioning in an aggressive form  
of human squamous carcinoma as a component of a recurrent t(15;19) chromosomal translocation [13,14]. 
It has been found to be involved in a wide range of immune-cell related cancers including acute 
myeloid leukemia (AML), mixed lineage leukemia (MLL) and diffuse large B cell lymphoma [15–18]. 
Recently, BRD4 has also been of great interest in diverse solid tumors. Many of those, such as  
non-small cell lung cancer, metastatic breast cancer and melanoma do not currently have effective 
conventional therapies, making BRD4 inhibition a very promising option by default [19–23]. 
The naturally existing isoforms of BRD4 and their functions are not fully understood since  
Scott R. Floyd and his groups [24] have shown that BRD4 encodes A, B and C three splice isoforms 
with two bromodomains and an extra-terminal (ET) domain presenting in each isoform. They 
demonstrated that the A isoform contains a carboxy-terminal domain (CTD), which is notably absent 
in the B and C isoforms, and it is replaced with a divergent short 75 amino-acid segment in the  
B isoform. Moreover, only the B isoform has the ability to inhibit DNA damage response signaling  
by recruiting the condensing II chromatin remodeling complex to acetylated histones through BRD 
interactions, leading to an uncontrolled cell-cycle progression. While other groups provided the 
evidences that the two isoforms of BRD4 (short isoform and long isoform) share the same N-terminal 
region except for the final three amino acids and have opposing roles in breast cancer growth and 
progression [20–22]. 
Motivated by the above rationale, small molecular selective inhibitors of bromodomains in BET 
proteins have been developed and it is likely that they will find broad application in medicine and basic 
research as exemplified by the recent significant effects in treating several disorders. Suppression of 
BRD4 using small compounds such as JQ1, I-BET151 and MS417 has been shown profound efficacy 
against a wide range of cancers such as diffuse large B cell lymphoma, AML, MLL, non-small cell 
lung cancer, breast cancer, pancreatic cancer and melanoma [10,15,16,19,23,25]. However, the role of 
BRD4 has not been well studied for colorectal cancer, with the exception of one paper demonstrated 
that overexpression of BRD4 reduced colorectal tumor growth in vivo [26]. In this paper, we 
demonstrate that BRD4 inhibition has a significant effect on CRC, and that it can curtail associated 
tumor metastasis.  
2. Results and Discussion 
2.1. BRD4 Is Highly Expressed in Colon Cancer Cells and Colon Cancer Tissues  
Since BRD4 has been implicated to be a critical player in the aforementioned cancers, we first 
explored to see if its expression was also of significance in CRC. Seven established colon cancer cell 
lines (LoVo, SW48, SW480, HCT8, HCT116, HT29 and SW620) were analyzed for expression of 
BRD4 and BRD2 relative to the normal colon cell FHC line by real-time PCR. Our results indicate that 
high levels of BRD2, as well as BRD4 isoforms (long and short) were present in colon cancer cells,  
Int. J. Mol. Sci. 2015, 16 1931 
 
 
as compared to normal colon epithelial cell (Figure 1A). To further confirm this finding, we analyzed 
expression of BRD4 on the protein level in colon cancer tissues. 45 paired samples of cancerous and 
healthy colon tissue from patients of different age, gender, disease state, and disease site were analyzed 
for BRD4 expression by Western blotting (Table 1). Overall, there was a noticeable higher expression 
of BRD4 in the tumor samples compared to healthy control (n = 45; p = 0.0005) (Figure 1B). Our 
analysis also revealed a potential age correlation for BRD4 expression, with older patients tending to 
have higher expression of the protein (n = 45, p = 0.11) (Figure 1C). More samples would be needed 
for confirmation. However, it seemed to be no correlation between the expression level of BRD4 and 
CRC stages (n = 45, p = 0.89) (Figure 1D). 
Table 1. Patients’ clinicopathological characteristics and Brd4 expression fold changes. 
Clinicopathological Characteristics 
Number (%) of Patients 
(n = 45, Paired) 
Age (years) 
20–49 9 (20.0) 
50–64 20 (44.4) 
≥65 16 (35.6) 
Gender 
Male 27 (60.0) 
Female 18 (40.0) 
Site of tumor 
Ascending colon 6 (13.3) 
Transverse colon 3 (6.7) 
Descending colon 3 (6.7) 
Sigmoid colon 13 (28.9) 
Rectum 20 (44.4) 
Histologic differentiation 
Well and moderately differentiated 
(≥50% gland formation) 
37 (82.2) 
Poorly differentiated  
(<50% gland formation) 
7 (15.6) 
Missing 1 (2.2) 
AJCC stage 
I 4 (8.9) 
II-A 6 (13.3) 
II-B 11 (24.4) 
III-A 0 (0.0) 
III-B 13 (28.9) 
III-C 5 (11.1) 
IV 6 (13.3) 
T classification 
T1 1 (2.2) 
T2 3 (6.7) 
T3 12 (26.7) 
T4 29 (64.4) 
N classification 
N0 21 (46.7) 
N1 15 (33.3) 
N2 9 (20.0) 
M classification 
M0 39 (86.7) 
M1 6 (13.3) 
Relative fold change of cases 
expressing Brd4 (Tumor/Normal) 
>1 31 (68.9) 
<1 14 (31.1) 




Figure 1. BRD4 is highly expressed in colorectal cancer (CRC). (A) mRNA expression 
levels of BRD2, BRD4 short isoform and BRD4 long isoform in normal colon epithelial 
cell lines and colon cancer cell lines; (B) Protein levels of BRD4 in normal and colon 
cancer human tissues (tumor and healthy control); (C) Protein levels of BRD4 according to 
different ages; (D) Protein levels of BRD4 according to the stage of CRC (per AJCC 
guidelines). BRD4S: BRD4 short isoform; BRD4L: BRD4 long isoform; BRD4C: 
Commercial BRD4 primer as positive control; CRC: colorectal cancer.  
2.2. Colon Cancer Cell Proliferation Is Potently Inhibited by BRD4 Inhibitor in Vitro 
Several different small molecules have been synthesized in recent years with the capability of 
selectively binding to the bromodomains of BRD4, inhibiting its function [15–17]. MS417 is one of 
them, and has been demonstrated to be effective in other reports [23,27–29]. After having observed 
that BRD4 is highly expressed in CRC, we next sought to determine the consequences that  
would follow from its inhibition. For this purpose, we treated five distinct colon cancer cell lines 
(HT29, HCT8, HCT116, SW480 and SW620) with a series of doses of MS417 ranging from 1 to  
30 μM, and then plotted out their survival rates relative to the concentration as determined by  
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) assay. Interestingly, survival rates varied 
dramatically between the various cell lines at low concentrations, with the survival rate of SW620 cells 
being double that of HT29 cells at a MS417 concentration of 1 μM (Figure 2A). Overall, HT29 
showed the highest sensitivity to MS417 at all doses and all time points tested, whereas SW620 
showed the lowest sensitivity in responding to BRD4 inhibition. All cell lines tested responded in  
a dose dependent fashion, with all of them experiencing near 100% inhibition at a concentration of  
12 μM (Figure 2A). Except in HCT116 cell line, for which the population remained consistently from 
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24 to 72 h, all cell lines also showed time dependent reduction at 24, 48 and 72 h incubations, as 
expressed as doses (Figure 2B). However, there appeared to be no obvious correlation between the 
amount of BRD4 protein expressed in a cell line and the effect of the MS417. Because of the striking 
differences in survival rates over the experimental MS417 treatment concentration range (1–12 μM) 
despite similar characteristics in several respects (such as with significant expression of the Myc 
oncogene, an enhancing element found to interact strongly with BRD4) (Table S1), HT29 and SW620 
were chosen for further investigation. 
To confirm those results, we performed colony formation assay to further clarify the anti-proliferative 
effects of MS417. As expected, the number of colonies of HT29 and SW620 decreased sharply in the 
presence of 1 μM MS417 (Figure 2C,D). The colonies that did develop in the MS417 treated groups 
were also smaller (Figure 2C). In fact, the MS417-treated HT29 group developed almost no colony 
growth, exhibiting a stronger response to MS417 than SW620 cells, results consistent with our MTT. 
Overall, our data also suggest that inhibition of BRD4 has potent antiproliferative effects on colon 
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Figure 2. BRD4 inhibition attenuates proliferation, migration and invasion in vitro.  
(A) 72 h survival rate curve of HT29, HCT8, HCT116, SW480 and SW620 treated with 
vehicle (DMSO) or MS417 (1, 3, 6, 9, 12, 24, 30 µM), measured by MTT; (B) IC50 of 
HT29, HCT8, HCT116, SW480 and SW620 following vehicle/MS417 for 24, 48 and 72 h; 
(C,D) macroscopic and microscopic images and quantification of colonies formed by 
HT29 or SW620 cell lines treated with MS417 (1 µM); (E,F) Cell migration and invasion 
of HT29 or SW620 cell lines were inhibited by MS417 (1 µM). n = 3 repeats with similar 
results. ** p < 0.01; *** p < 0.001. Values are depicted as Mean ± SEM. 
2.3. Colon Cancer Cell Migration and Invasion Are Reduced by BRD4 Inhibition in Vitro 
Both HT29 and SW620 are invasive cancer cells with significant metastatic potential [30,31]. 
Consequently, we performed migration and invasion assay using transwell to verify if MS417 also 
attenuates the metastatic capability of these lines. After treatment with MS417 for 48 h, cell counts for 
both HT29 and SW620 reduced significantly compared to control, indicating a significant reduction in 
cellular movement. The migratory and invasive behavior of HT29 cells was largely curtailed as a result 
of the addition of MS417. Although less noticeable change was discovered in the SW620 cell line, the 
reduction of migration and invasion were still statistically significant (Figure 2E,F). While the cell 
counts may have also been influenced by the toxic effect of MS417, there was no evidence that the 
cellular debris was blocking migration, and the magnitude of the difference in counts between treated 
and untreated groups makes the results statistically significant regardless. Based on data above, BRD4 
inhibition via MS417 appears to capably suppress CRC cell migration and invasion, suggesting that 
BRD4 plays a key role in these processes. 
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2.4. BRD4 Inhibition Alters Protein Expression in CRC Cells 
Having seen that BRD4 inhibition leads to the reduction of the proliferative ability of CRC cell 
lines HT29 and SW620, we next tried to elucidate the means by which that effect was generated.  
We first investigated whether or not the cells were experiencing increased apoptosis as a result of 
MS417 application. Flow cytometry staining with standard apoptosis markers Annexin V and PI 
showed minimal increases in the number of apoptotic cells (Figure 3A). Mixed results were observed 
through Western blotting, with Fas, an important cell surface receptor protein of the TNF receptor 
family, which induces apoptosis on binding Fas ligand, increased after BRD4 inhibition in both cells  
(Figure 3B). Interestingly, increased expression of some anti-apoptotic factors (such as XIAP) was also 
observed in HT29. However, the expression of XIAP decreased in SW620 (Figure 3B). It seems clear 
that apoptosis was not the controlling factor for BRD4-inhibition mediated suppression of the cells. 
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Figure 3. BRD4 inhibition impacts transcriptional programs that control cell proliferation 
and EMT. (A) Apoptosis of HT29 and SW620 cell lines treated with vehicle (DMSO), 
MS417 (1 µM) or MS417 (12 µM); (B) Protein levels of candidate apoptosis-related 
factors following vehicle/MS417 treatment (1 and 12 µM) for 48 h; (C) Protein levels of 
E-cadherin and Vimentin in HT29 or SW620 cell lines treated with vehicle or MS417  
(1 and 12 µM). The expression level of each protein was normalized against GAPDH.  
* p < 0.01; ** p < 0.001; n.s. not significant. 
We then searched for alternative changes that could explain the dramatic reduction of migration and 
invasion has been seen in HT29 and SW620 after BRD4 inhibitor treatment. As mentioned previously, 
we had noticed a curious change in the shape and size of the cells as a result of BRD4 inhibition from 
the colony growth assays. Based on those results, we investigated for changes in structural proteins, 
and in proteins involved in epithelial-mesenchymal transition (EMT). Results revealed that protein 
level of epithelial marker E-cadherin increased sharply in HT29 even at a low dose as 1 μM, while it 
only showed a significant increase at a higher dose in SW620. These results were consistent with  
our findings in previous drug sensitive tests, which HT29 present the highest sensitivity to MS417  
(Figure 3C). Expression level of vimentin, a mesenchymal marker, which is required for EMT, only 
decreased at a high dose in both cell lines (Figure 3C). These results confirmed our theory that the 
inhibition effect of BRD4 inhibitor on cell migration and invasion is at least in part due to EMT inhibition. 
2.5. BRD4 Inhibition Impairs Colon Cancer Tumor Growth in Vivo 
To further examine the antitumorigenic potential of BRD4 inhibition in vivo, we next used a classical 
xenograft mouse model. Nude mice were grafted via injection of HT29 or SW620 into the left or right 
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flanks. Mice then received treatment (MS417 at 20 mg/kg) or sham (DMSO) over the course of three 
weeks, with the first treatment beginning on the second day. By tracking the development of tumor 
volume and tumor weight, we found that mice treated with BRD4 inhibitor displayed a significant 
reduction in tumor growths of both cell lines (Figure 4A,B). Interestingly, tumors in SW620 cells were 
also largely reduced by MS417, indicating that SW620 cells also showed a high sensitivity to BRD4 
inhibitor in vivo (Figure 4C), in contrast with a relatively much lower sensitivity in MTT assay. The 
high degree of proliferation of SW620s in the group treated with sham further demonstrates that the 
lineage behaves very differently in vivo as compared to in vitro. HT29 cells, on the other hand, 
displayed similar growth and sensitivity both in vivo and in vitro, and HT29 tumors in the treated mice 
were also highly suppressed (Figure 4C). Overall health effects on the mice were also monitored over 
the course of MS417 treatment, with mice weights taken at every treatment time. Our results show that 
group of mice treated with MS417 also had more stable weights as compared with the placebo group 
(Figure 4D). The changes were pronounced for both injected cell lines. Collectively, these results 
indicate that MS417 may effectively clear tumor cells in vivo without fatal consequences. 
 
Figure 4. BRD4 inhibition impairs CRC tumor growth in vivo. (A) Macroscopic images of 
resected tumors at the conclusion of the experiment; (B) average weight of resected 
tumors; (C) average tumor volume of mice injected with either vehicle (DMSO) or MS417 
(20 mg/kg, n = 4/treatment); (D) average mice weights with every 2-day injection of 
vehicle/MS417 over a time course of 3 weeks. *, p < 0.05; **, p < 0.05; ***, p < 0.001. 
Values are depicted as Mean ± SEM. 
2.6. BRD4 Inhibition Suppressed Colon Cancer Liver Metastasis in Nude Mice 
Liver metastasis commonly occurs in conjunction with CRC, and is obviously highly detrimental.  
It was also a natural extension of our investigation, given that metastasis requires EMT and 
intracellular communication. Based on the promising effect BRD4 inhibition had on curtailing the 
migration and invasion of colon cancer cell lines in vitro and our results indicating changes it induced 
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in EMT, we next used a liver metastasis model to further confirm our results in vivo using HT29 and 
SW620 cells. BRD4 inhibitor MS417 was administered by intraperitoneal injection every two days, 
starting two days after tumor cell inoculation into the spleen. After three weeks, all of the mice injected 
with SW620 developed liver tumors. In the HT29 group however, only 40% of the mice treated with 
MS417 exhibited liver metastasis, while all of the ones treated with sham (DMSO) developed tumors 
(Figure 5A,B). Both cell lines showed significant inhibition of metastatic capability with the number  
of metastases in liver dropping by over an order of magnitude, and fewer liver micrometastases  
per liver section, following BRD4 inhibition (Figure 5C,D). This result was somewhat unsurprising, 
since tumor metastasis relies on significant intercellular communication and signal propagation. The 
complete blockage of metastasis of HT29 in some mice treated with BRD4 inhibitor clarifies the need 
for BRD4 in EMT. Collectively, these results further support our hypothesis that the in vitro effect of 
EMT and signaling suppression following BRD4 inhibition is also present in vivo. 
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Figure 5. BRD4 inhibition suppresses CRC liver metastasis in vivo. (A,B) Macroscopic 
images of resected livers at the conclusion of the experiment in mice injected by HT29 or 
SW620 cell lines and then treated by vehicle/MS417 (20 mg/kg, n = 5/treatment);  
(C,D) Representative microscopic H&E images of livers. Metastatic focus is circled.  
*** p < 0.001. Values are depicted as Mean ± SEM. 
3. Discussion 
The development and optimization of small-molecule modulators of epigenetic targets as cancer 
therapeutics is a major collaborative focus of current biomedical research groups. BRD4, an important 
transcription mediator, binds to acetylated histones to influence transcription and thus stimulate  
or inhibit gene expression [11,32]. BRD4 is implicated in transmitting epigenetic memory and 
functions as an associated factor of the positive transcriptional elongation factor b (P-TEFb), which 
plays an important role in cell cycle progression [33,34]. In fact, BRD4 is expressed ubiquitously  
in different tissues and is indispensable in cellular growth. Knockout of Brd4 in mice is embryonic 
lethal, and mouse BRD4 knockout embryonic stem cells do not growth in culture [11,35]. 
In most previous studies, BRD4 is thought to exist in two spliced isoforms with opposing roles  
in tumor growth and progression [20–22]. They provided the evidences that BRD4 long isoform 
reduced metastasis, however short isoform enhanced metastasis in breast cancer through interactions 
with the metastasis susceptibility protein RRP1B and SIPA1 [22]. They further demonstrated that 
BRD4 short isoform is a nuclear membrane-associated protein, while the long isoform is associated 
with the nuclear matrix and the short isoform might be an indirect competitive inhibitor of the long 
isoform [22]. Thus, we tested mRNA expression level of both BRD4 short and long isoforms in CRC. 
Unexpectedly, both isoforms showed a higher expression in various colon cancer cell lines comparing 
to normal colon epithelial cell. On the other hand, we observed a higher protein expression level of 
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BRD4 in 45 colon cancer tissues, which were collected from China. It is interesting that the molecule 
weight of BRD4 antibody used in this study is around 150 kDa, while the full length of BRD4  
is supposed to encode a 1362 amino acid protein with a molecular weight of 200 kDa [9,11]. If so, 
further structure analysis of BRD4 isoforms would be necessary for revealing the association between 
BRD4 expression level and its role in colon cancer tumorigenesis and metastasis, although we have 
found that BRD4, most likely the short isoform, has an increasing expression in both colon cancer cell 
lines and colon cancer tissues, indicating a pro-oncogenic role in CRC. 
Given the rationale evidence above, we next hypothesized that CRC might be inhibited by BRD4 
inhibitor. Not surprisingly, reduction of cell proliferation by MS417, a novel BRD4 inhibitor, provides 
a clear indication that BRD4 may be closely related to CRC tumorigenesis. A restrained migratory and 
invasive capability of colon cancer cells inhibited by MS417 reveals that BRD4 plays a critical role in 
metastasis, although this does not mean that BRD4 is the only protein that functions importantly in this 
progression. During the past decades, small-molecular inhibitors of BRD4 are becoming the subject of 
intensive investigation. MS417 was first designed to block BRD4 binding to the acetylated NF-κB, 
which effectively attenuates NF-κB transcriptional activation of pro-inflammatory genes [27]. MS417 
is structurally related to I-BET and shares the same thieno-tria-zolo-1,4-diazepine scaffold as JQ1. The 
main difference between MS417 and JQ1 is that the former consists of a methyl ester, which is much 
smaller than the replacement in latter so that it can interact with Leu-95, Tyr-97 and Tyr-139 in a small 
hydrophobic cavity formed between the ZA and BC loops [27]. MS417 has been reported to have 
efficacy effect on HIV-associated kidney disease and recently has been indicated in sustaining 
melanoma proliferation [23,27–29]. We have paid close attention to several previous studies, which 
showed that BRD4 inhibitor seemed to be effective only at inhibiting primary tumor growth. I-BET151 
has been showed unable to reduce pulmonary metastasis in breast cancer and the decrease of lung 
metastasis burden of melanoma by MS417 has the similar result [22,23]. However, in the present 
paper, we observed a sharp inhibition of invasiveness and migration properties in colon cancer cell 
lines, as well as a significant reduction of metastasis in vivo. Our results suggest several plausible 
explanations. First, different isoforms of BRD4 may exist in different cancers and the account of  
each isoform may vary in different cell lines, which is consistent with our study that both short isoform 
and long isoform express in colon cancer cells; Second, we couldn’t make a conclusion that the two 
isoforms have opposing functions, but it is possible that they might somehow be controlled and 
regulated by each other. Overexpression and reduction of any isoform will result in disorder and 
disfunction in both; Third, the two isoforms might be not inhibited equally by the inhibitor. Since 
previous study has demonstrated that BRD4 short isoform has an expanded histone binding range 
compared to long isoform. It is also reported that casein kinase II phosphorylation may induce 
conformational changed in BRD4 long isoform that alters bromodomain II accessibility, which may 
result in a differential activity to BRD4 inhibitors. It is no doubt that further investigation will  
be required to determine the mechanism in interaction between BRD4 isoforms and inhibitors. 
Colorectal cancer, like many other adenocarcinomas, often spreads throughout the body via EMT, 
and the discovery of distant metastasis has been strongly correlated with worsened prognosis—current 
AJCC staging classifications of CRC deem a positive test for metastasis to be indicative of progression 
to stage IV. As a result, interventions that can control tumor spread and limit EMT are of great utility 
in treating CRC. As other results as well as ours have shown, suppression of these communication 
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channels can strongly inhibit the ability of tumors to metastasis, a result that is of great benefit  
if achieved in clinical practice [36].  
It is possible, of course, that such EMT and signaling disruption was caused in part by the necrosis 
induced by BRD4 inhibition. However, our result suggest that necrosis alone could not fully account 
for the disruption, as the disruption could be seen on a protein level even at fairly low concentrations 
of MS417, when the survival rate of the cells was near full. These protein level changes were reflected 
in both in vitro and in vivo results. Future studies may uncover more precisely the exact contributions 
of the inhibition of BRD4 and necrosis to the results observed. BRD4 is a multifunctional protein, and 
its potential interaction with proteins involved in EMT and intercellular signaling are not completely 
unexpected. Work done by other groups has demonstrated that Twist, an EMT mediator, interacts with 
BRD4 after deacetylation [37]. Other groups have shown that the C-terminus domain is critical for 
BRD4 induction of EMT [21]. These results may be of use in conceiving new therapies for CRC that 
might use BRD4 inhibition to control tumor expansion, making it easier for the tumor to be eliminated 
in place (likely in conjunction with other chemotherapy medicines). Furthermore, the differences 
between mice that allow for some to have liver metastasis completely blocked off following BRD4 
inhibition merits additional study, as such work may identify novel factors that act in conjunction with 
BRD4 inhibition to produce that result. Further work will be needed to clarify the exact contributions 
of each interaction, which BRD4 inhibition may be disrupting in CRC. After all, other proteins besides 
Twist, such as Snail and Zeb1, have been found to work as transcription activators to up-regulate  
EMT [38,39], and may also be interaction partners with BRD4.  
Given the increasing popularity of multi-drug chemotherapy regimens, the identification of additional 
functional roles and pathways provides essential information for therapy design. The anti-metastatic 
effect of BRD4 may allow for it to fill a valuable function in anti-CRC treatments. For instance,  
the anti-foliate medication methotrexate is in widespread use for its tumorcidal abilities [40,41]. 
However, folate deprivation has also been demonstrated to promote CRC cell invasion [42]. A BRD4 
inhibitor may potentially serve to suppress induced invasion, as an alternative to simply increasing the 
dosage of methotrexate. In addition, several commonly used chemotherapy drugs, such as paclitaxel 
have been demonstrated to also induce resistance, through the promotion of inflammation along the 
NF-κB pathway [43]. BRD4 inhibition has been shown to capably suppress NF-κB transcription and  
function [17,27]. Given the constant search for effective therapies that are effective at lower doses of 
medication (in the interest of limiting side effects), such potential combinations may have useful 
clinical applications.  
In summary, our findings demonstrate that BRD4 is a positive regulator in colorectal cancer, 
playing a key role in tumor metastasis. We demonstrate that one BRD4 inhibitor is effective in suppressing 
cancer growth and preventing distal metastasis through multiple means. The latter role may allow 
BRD4 inhibitors to be suitable additions to existing chemotherapy regimens in colorectal cancer.  
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4. Experimental Section  
4.1. Cell Culture 
All cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, 
USA). The human normal colon epithelial cells (FHC cell line) were grown in a DMEM:F12 Medium 
(ATCC) supplemented with 10% heat-inactivated bovine fetal serum (FBS; Gibco, Grand Island, NY, 
USA), 100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrigen, Camarillo, CA, USA), extra  
10 mM HEPES (Gibco), 10 ng/mL cholera toxin (Sigma-Aldrich, St. Louis, MO, USA), 0.005 mg/mL 
transferrin (Sigma-Aldrich) and 100 ng/mL hydrocortisone (Sigma-Aldrich). The human colon  
cancer cell lines HT29, LoVo, SW48, SW480, HCT8, HCT116 and SW620 were maintained in 
Dulbecco’s modified Eagle’s Medium (DMEM) with 10% FBS, 100 U/mL penicillin and 100 µg/mL 
streptomycin. Cells were cultured at 37 °C in an incubator containing 5% CO2. 
4.2. Patient Samples 
This study included 45 paired colorectal cancer samples (Table 1), which were obtained from 
patients who underwent colonoscopy between January 2011 to January 2012 at Southern Medical 
University, Guangzhou, China. This study was reviewed and approved by the Institution Ethical 
Review Boards of Southern Medical University. Samples were kept at −80 °C until analysis. The 
histological diagnosis of resected specimens was confirmed by at least two well-trained pathologists. 
Total protein from each sample was extracted as following: 1 mL of 1× lysis buffer (Cell Signaling 
Technology, Danvers, MA, USA) with 1× protease inhibitor cocktail (Roche Applied Science, 
Indianapolis, IN, USA) and 1× phosphatase inhibitor cocktail was added to each tissue sample and the 
lysate was sonicated twice for 15 s each time on ice, and then centrifuged at 14,000 rpm for 30 min at 
4 °C. The protein concentration was determined using BCA Protein Assay kit (PIERCE, Rockford, IL, 
USA) and analyzed via Western blotting. 
4.3. Real-Time PCR 
Total RNA was extracted using TRIzol reagents (Life Technologies, Carlsbad, CA, USA), 
according to the manufacturer’s instructions. RNA samples were reverse transcribed at 50 °C for  
50 min, using the high-capacity cDNA reverse transcription kit (SuperScript; Life Technologies, 
Carlsbad, CA, USA) according to the standard protocol of the supplier. Sequences of the PCR primers 
used are as follows: β-actin primer forward: 5'-CCAGAGCAAGAGAGGCATCCT-3' and reverse:  
5'-TAGATGGGCACAGTGTGGGTGA-3'; BRD2 primer forward: 5'-GTCAAACTGG GTCTACC 
GGATT-3' and reverse: 5'-CTTTTCCAGCGTTTGTGCCA-3'; BRD4 short isoform primer forward:  
5'-ACAACAAGCCTGGAGATGACA-3' and reverse: 5'-GTTTGGTACCGTGGAAACGC-3'; BRD4 
long isoform primer forward: 5'-CCGGAAATGAAGCCTGTGGAT-3' and reverse: 5'-TTTTCA 
GGTCCTTTTTGGGCG-3'; Commercial BRD4 primer (Qiagen, Valencia, CA, USA) was used as 
positive control. Real-time PCR was carried out using LightCycler® 480 Real-Time PCR System 
(Roche Diagnostics, Penzberg, Germany). Amplification system included 15 μL of SYBRGreen Mix 
(10 μL), ddH2O (1 μL), cDNA (2 μL), forward primer (1 μL) and reverse primer (1 μL). The results of 
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real-time PCR were analyzed by the DCT method: ΔCt = Ct selected gene − Ct β-actin, RQ (Relative 
Quantitation) = 2−ΔCt × 100%. The results of real-time PCR were presented as the ratio between the 
selected genes and β-actin transcripts. All experiments were performed in triplicates.  
4.4. MTT Assay 
MTT assay was performed to assess the IC50 of BRD4 inhibitor. Cells were seeded at 2 × 103 cells 
per well on a 96-well plate. The day after (day 0), cells were treated with DMSO or with increasing 
doses of MS417 (1, 3, 6, 9, 12, 24, 30 µM) and cultured for another 3 days. The  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) solution as added to each well and then 
the plates were cultured for 2 h at 37 °C. The Medium was removed and cells were stained with  
0.1% crystal violet. Crystals were dissolved in DMSO and optical density was read at 590 nm. 
Experiments were repeated three times, and data represented as the mean of sextuplicate wells ± SEM. 
4.5. Colony Formation Assay 
Cells were seeded at 250 cells per well in 6-cm well plates (n = 3). Cells were then treated with 
MS417 after 1 day, and culture cells over 10 days. The cells were then stained with crystal violet, 
photographed, and counted.  
4.6. In Vitro Migration and Invasion Assay 
Equal numbers of cells (3 × 105) in DMEM complemented with 2% FBS were added to the upper 
compartment of a Transwell chamber (8 µm, Costar, Cambridge, MA, USA) and kept at 37 °C for  
48 h. As a chemoattractant, the lower compartment contained DMEM supplemented with 10% FBS. 
At the end of the incubation period, cells from the upper surface of the filter were wiped off with  
a cotton swab. Cells on the lower surface of the filter were fixed with 2% formaldehyde for 30 min and 
then stained with 0.1% crystal violet. The number of cells having migrated to the bottom of the 
chamber was counted in the light microscope on ten randomly selected fields. The mean number of 
cells was calculated per field. Three sets of experiments were carried out, each in triplicate. For the 
matrigel assay, the filter was replaced by a BD BioCoat Matrigel invasion chamber (BD Bioscience, 
Mountain View, CA, USA). 
4.7. Annexin V/PI Assays for Apoptosis 
For Annexin V/PI assays, cells were stained with Annexin V-FITC and PI, and evaluated for 
apoptosis by flow cytometry according to the manufacturer’s protocol (BD PharMingen, San Diego, 
CA, USA). Briefly, 1 × 106 cells were washed twice with phosphate-buffered saline (PBS), and stained 
with 5 µL of Annexin V–FITC and 10 µL of PI (5 µg/mL) in 1× binding buffer (10 mm HEPES,  
pH 7.4, 140 mm NaOH, 2.5 mm CaCl2) for 15 min at room temperature in the dark. The apoptotic 
cells were determined using a flow cytometer (FACSCalibur, BD Biosciences). Both early apoptotic 
(annexin V-positive, PI-negative) and late (annexin V-positive and PI-positive) apoptotic cells were 
included in cell death determinations. 
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4.8. Western Blot Analysis 
HT29 and SW620 cells were seeded onto 10 cm dish at a density of 1 × 106. The day after, cells 
were completely adherent and then treated with MS417 at doses of 1 and 12 µM or with DMSO  
as control. Keep culturing for 48 h, cells were harvested by the end of the experiment. Proteins were 
extracted as descrbed as before. For Western blot assay, proteins (20 µg) were boiled for 5 min and 
resolved by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred 
from gels to nitrocellulose membranes. The membranes were blocked with 3% BSA for 1 h at room 
temperature and incubated with primary antibodies at 4 °C overnight. All primary antibodies used were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The second day, membrane was 
incubated with secondary antibodies conjugated with horseradish peroxidase (Amersham, Arlington, 
Height, IL, USA) for 1 h at room temperature. The membrane was developed with chemiluminescence 
substrate (Immun-Star™ HRP Peroxide Buffer/Immun-Star™HRP Luminol Enhancer) (Bio-Rad, 
Hercules, CA, USA). The grey value of each protein was measured using freeware ImageJ and 
normalized by the standard control protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
4.9. Mouse Xenograft and Liver Metastasis Model 
All procedures involving animals were approved by Animal Care and Use Committee (Approval 
number SYXK 2011-0074) of Southern Medical University. Surgery was performed using sodium 
pentobarbital anesthesia. Twenty-eight female BALB/c-nu nude mice (16–20 g) aged 5–7 weeks were 
obtained from Guangdong Province Medical Experimental Animal Center and were used to build two 
models. HT29 cells and SW620 cells were injected (5 × 106/Mouse) subcutaneously in the left and 
right flanks of nude mice. Two days after, mice were randomized into 2 groups, 4 mice per each group 
and treated intraperitoneally with vehicle (2.5% DMSO) or with 20 mg/kg MS417 every 2 days. 
Tumor volume and mouse weight were measure every 2 days during 3 weeks. Tumor weight was 
analyzed when the tumors were excised at the end of the experiment. For the liver metastasis model, 
HT29 cells or SW620 cells were transplanted (1.5 × 106) intrasplenically. MS417 or DMSO were 
administered by intraperitoneal injection every 2 days, starting 2 days after tumor cell inoculation. 
After treating the mice with MS417 or placebo for 3 weeks, liver was removed and metastatic tumors 
on surface of liver were measured. Afterward, tissues were fixed in 10% formalin, paraffin embedded, 
and 5 µm sections were hematoxylin and eosin (H&E)-stained. 
4.10. Statistical Analysis 
Statistical analyses were performed with MS Excel and GraphPad Prism (5.01 for Windows; 
GraphPad Prism Software Inc., San Diego, CA, USA), version 17.0 (SPSS, Inc., Chicago, IL, USA). 
Mean values ± SEM are representative of one of three independent experiments. Statistical 
significance was determined by unpaired t test. Of note, * p < 0.05; ** p < 0.01 and *** p < 0.001.  
5. Conclusions 
A multifunctional protein that can influence the behavior of many proteins, BRD4 has been the 
subject of significant scrutiny. In our present paper, we suggest that BRD4 has a role in colorectal 
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cancer and epithelial-mesenchymal transition, in addition to the previous functions discovered. We 
also report the success of using BRD4 inhibitor to target colorectal cancer cell growth in vivo, albeit 
through xenografts. Further confirmation of these phenomena may help to further inform future use of 
BRD4 inhibitors, and guide the testing of additional compounds for use in specialized chemotherapy 
regimens. Future studies may also identify other proteins of interest related to these proteins altered 
during the course of BRD4 inhibition. 
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